A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

Part of paid clinical trials in Lancaster, California.

Sponsor
Kinaset Therapeutics Inc
Study ID
NCT07532265
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Frevecitinib — DRUG
    Frevecitinib (KN-002) delivered via a dry powder inhaler (DPI)
  • Placebo — DRUG
    Matching placebo to frevecitinib

Study Details

A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) Over a 12-Week Treatment Period in Patients With Severe Asthma Not Controlled With Medium to High Dose ICS/LABA

Key Dates

First listed
Apr 15, 2026
Start date
Jul 16, 2026
Status verified
Jul 2026
Primary completion
Nov 30, 2027
Completion
Nov 30, 2027

Study Design

Enrollment
512 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Frevecitinib Dose 1
    Drug: Frevecitinib
  • Experimental: Frevecitinib Dose 2
    Drug: Frevecitinib
  • Experimental: Frevecitinib Dose 3
    Drug: Frevecitinib
  • Placebo Comparator: Frevecitinib (KN-002) matching placebo
    Placebo

Primary Outcome Measure

Pre-BD FEV1 [ Time Frame: Week 12 ]

Locations (14)

FacilityCityStateZIPSite coordinators
Research siteLancasterCalifornia93534
Kinaset investigative site
855-818-2289
Research siteSan JoseCalifornia95117
Kinaset investigative site
855-818-2289
Research siteBrandonFlorida33511-
Research siteMiamiFlorida33137
Kinaset investigative site
855-818-2289
Research siteTampaFlorida33607
Kinaset investigative site
855-818-2289
Research siteChicagoIllinois60612-
Research siteKansas CityMissouri66160-
Research siteCharlotteNorth Carolina28277
Kinaset investigative site
855-818-2289
Research sitePittsburghPennsylvania15213-
Research siteRock HillSouth Carolina29732
Kinaset investigative site
855-818-2289
Research siteDallasTexas75225
Kinaset investigative site
855-818-2289
Research siteHoustonTexas77099
Kinaset investigative site
855-818-2289
Research siteSan AntonioTexas78258
Kinaset investigative site
855-818-2289
Research siteWilliamsburgVirginia23188-

Find similar trials in Lancaster, CA

Nationwide
Asthma trialsPulmonology trialsLung disease trials
By condition
Asthma
By specialty
PulmonologyLung disease

Related Studies